Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,154 matching trials from the live ClinicalTrials.gov search.

Filters: San Antonio, Texas Clear all

Conditions: Dental Pulp Necrosis, Periapical Periodontitis
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 16 Years to 60 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cutaneous Melanoma, Stage II
Interventions: Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin; Procedure
Lead sponsor: Melanoma and Skin Cancer Trials Limited; Other
Eligibility: 18 Years and older
Enrollment: 2,998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2034
U.S. locations: 128
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more

Conditions: Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Interventions: Placebo capsules, Bardoxolone methyl capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 37
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 30 more

Conditions: Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide; Procedure · Biological · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 70
States / cities: Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more

Conditions: Liver Transplant
Interventions: OCS Liver System; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 1 more

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Eculizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more

Conditions: Prostate Cancer
Interventions: three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2031
U.S. locations: 454
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more

Conditions: Leukemia, Myeloid, Acute, AML
Interventions: PTC299; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Aurora, Colorado • New Haven, Connecticut • Detroit, Michigan + 14 more

Conditions: Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 13 Years and older
Enrollment: 2,565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 39
States / cities: Tucson, Arizona • Davis, California • Orange, California + 31 more

Conditions: Oligometastatic Malignant Solid Neoplasm
Interventions: Best Practice, Local Consolidation Therapy; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • Little Rock, Arkansas • Honolulu, Hawaii + 8 more

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 31 Years
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more

Conditions: Epilepsy, Seizures, Drug Resistant Epilepsy
Interventions: Vagus Nerve Stimulation (VNS) Therapy; Device
Lead sponsor: LivaNova; Industry
Eligibility: Not listed
Enrollment: 827 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 19
States / cities: Grand Junction, Colorado • Washington D.C., District of Columbia • Orlando, Florida + 15 more

Conditions: HER2-Positive Early Breast Cancer
Interventions: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 9
States / cities: Lakewood, Colorado • Peoria, Illinois • Wichita, Kansas + 5 more

Conditions: Organ Transplantation
Interventions: RIPC (Remote Ischemic Preconditioning); Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 6 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Newark, New Jersey • San Antonio, Texas

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 38
States / cities: Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 34 more

Conditions: Crohn's Disease
Interventions: vedolizumab, Placebo; Drug · Other
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 110
States / cities: Birmingham, Alabama • Los Angeles, California • Montebello, California + 91 more

Conditions: Dental Caries
Interventions: 0.24% Sodium Fluoride Dentifrice, 1.5% Arginine Dentifrice, 4.0% Arginine Dentifrice, 8.0% Arginine Dentifrice; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 10 Years to 14 Years
Enrollment: 2,025 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Loma Linda, California • Gainesville, Florida • Indianapolis, Indiana + 4 more

Conditions: Psoriasis
Interventions: BMS-986165, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 89
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 75 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Brief Cognitive Behavioral Treatment, Minimal Contact; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Lackland Air Force Base, Texas • Randolph Air Force Base, Texas

Conditions: Cardiac Arrest
Interventions: Therapeutic Hypothermia, Therapeutic Normothermia; Procedure · Other
Lead sponsor: University of Michigan; Other
Eligibility: 48 Hours to 18 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Leukemia
Interventions: filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 1 Year
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2012
U.S. locations: 128
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 114 more

Conditions: Alveolar Ridge Defect
Interventions: CopiOs Pericardium Membrane; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Aurora, Colorado • Indianapolis, Indiana • Houston, Texas + 1 more

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 66 Years and older
Enrollment: 9,682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 2
States / cities: Bedford, Massachusetts • San Antonio, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Belimumab 1 mg/kg, Belimumab 10 mg/kg; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 67
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 56 more

Search by objective public record fields.

Measurement of Bite Force in Humans

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

OCS Liver DCD Trial

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

The Second Multicenter Hemophilia Cohort Study

Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

Remote Ischemic Preconditioning in Neurological Death Organ Donors

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Brief Cognitive Behavioral Treatment of Deployment-Related PTSD Symptoms in Primary Care Settings

Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial

Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

CopiOs® Pericardium Membrane for Localized Alveolar Ridge Augmentation

Factors Associated With in Suboptimal Prescribing for Older Patients With Epilepsy

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus